1-12 of 12
Hengbang Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Embryonic Ectoderm Development (EED) Inhibitor APG5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin Insufficiency in Preclinical Models of Anemia

Yifan Zhai, Yan Yin, Eric Liang, Hengbang Wang, Ping Min, Dajun Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5268.
https://doi.org/10.1182/blood-2023-185127
Published: 2023
Journal Articles

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Keshu Zhou, Mingyuan Sun, Xu Wei, Shuhua Yi, Junyuan Qi, Weiqi Nian, Guohui Cui, Jishi Wang, Xiaoping Zhang, Hong Cen, Fuling Zhou, Jianying Huang, Huilan Liu, Aizong Shen, Liangquan Geng, Ru Feng, Chongyuan Xu, Wenbin Qian, Fei Li, Lihong Liu, Caixia Li, Xielan Zhao, Jie Jin, Hongmei Jing, Dongmei Ji, Fangfang Lyu, Zi Chen, Lichuang Men, Hengbang Wang, Ke Zhang, Liang Xu, Zhang Zhang, Dajun Yang, Jianxiang Wang, Jianyong Li, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1900.
https://doi.org/10.1182/blood-2023-183071
Published: 2023
Journal Articles

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Junyuan Qi, Xudong Wei, Qiubai Li, Chukang Chang, Fuling Zhou, Jianying Huang, Yu Zhang, Chongyuan Xu, Xiaowen Tang, Qian Jiang, Junmin Li, Qun Qin, Qun He, Sujun Gao, Liping Liu, Zi Chen, Min Yu, Jing Wang, Lichuang Men, Hengbang Wang, Mohammad Ahmad, Dajun Yang, Yifan Zhai, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5954.
https://doi.org/10.1182/blood-2023-184959
Published: 2023
Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Elias Jabbour, Hagop M. Kantarjian, Paul B. Koller, Omer Jamy, Vivian G. Oehler, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Jorge Cortes, Huanshan Guo, Zi Chen, Lei Fu, Hengbang Wang, Lixin Jiang, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1798.
https://doi.org/10.1182/blood-2023-187744
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Elias Jabbour, Paul B. Koller, Vivian G. Oehler, Omer H Jamy, Sudipto Mukherjee, Anthony M. Hunter, Maria R. Baer, Joseph T. Beck, Zi Chen, Huanshan Guo, Lei Fu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian, Lixin Jiang, Cunlin Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 200–202.
https://doi.org/10.1182/blood-2022-162387
Published: 2022
Journal Articles

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Qian Jiang, Zongru Li, Ya-Zhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 198–199.
https://doi.org/10.1182/blood-2022-170868
Published: 2022
Journal Articles

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Matthew S. Davids, Asher Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kriachok, Hanna Usenko, Vladimir Ivanov, Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk, Alexander Myasnikov, Zvenyslava Maslyak, Andrew Proidakov, Olga Uspenskaya, Elena Borisenkova, Paula Marlton, Tanya Siddiqi, Allison Winter, Tamila Lysa, Bulat Bakirov, Lei Fu, Zi Chen, Min Yu, Mingyu Li, Laura Glass, Mohammad Ahmad, Olena Karpenko, Iurii Osipov, Asit De, Ben Paudyal, Hengbang Wang, Robert Winkler, Nashat Gabrail, Vinod Ganju, Tatiana S. Konstantinova, Olga S. Samoylova, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2022) 140 (Supplement 1): 2326–2328.
https://doi.org/10.1182/blood-2022-160386
Published: 2022
Journal Articles

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

Jiang Qian, Dayu Shi, Zongru Li, Yazhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 311.
https://doi.org/10.1182/blood-2021-153065
Published: 2021
Journal Articles

Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Ming Lu, PhD, Chenhui Deng, PhD, Yifeng Xiong, PhD, Hengbang Wang, Ping Xu, PhD, Lichuang Men, Tanhong Xie, Qian Jiang, MD, Zi Chen, MD, Qian Niu, MD, Ping Liu, PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-141268
Published: 2020
Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, MD, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, MD, Weiming Li, PhD, Xiaoli Liu, Na Xu, Yongping Song, MD, Yanli Zhang, Li Meng, MDPhD, Zhenya Hong, MDPhD, Bingcheng Liu, Shan Zeng, Lichuang Men, Yan Li, MD, Suning Chen, Mengxing Xue, PhD, Huanling Zhu, MD, He Li, Xin Du, Jin Lou, MD, Xiaohan Zhang, Yang Liang, MD, Yujun Dai, MD PhD, Ming Lu, PhD, Hengbang Wang, Jiao JI, PhD MD, Changai Yue, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142142
Published: 2020
Journal Articles

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3 rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, Lichuang Men, Hengbang Wang, PhD, Jiao JI, PhD MD, Bo Huang, Dayu Shi, Ting Zhao, Yue Hou, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 493.
https://doi.org/10.1182/blood-2019-124295
Published: 2019
Journal Articles

Safety and Efficacy of HQP1351, a 3 rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study

Qian Jiang, MD, Xiao Jun Huang, Zi Chen, MD, Lichuang Men, Wei Liu, Xuemei Sun, Jiao JI, PhD MD, Hengbang Wang, Yue Hou, Po Hu, Lei Zou, Hua Yan, Yingjie Huang, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 791.
https://doi.org/10.1182/blood-2018-99-119142
Published: 2018